for the Surgical Care and Outcomes Assessment Program Collaborative BACKGROUND: Surgical site infections (SSI) are an important source of morbidity and mortality. Chlorhexidine in isopropyl alcohol is effective in preventing central venous-catheter associated infections, but its effectiveness in reducing SSI in clean-contaminated procedures is uncertain. Surgical studies to date have had contradictory results. We aimed to further evaluate the relationship of commonly used antiseptic agents and SSI, and to determine if isopropyl alcohol has a unique effect. STUDY DESIGN: We performed a prospective cohort analysis to evaluate the relationship of commonly used skin antiseptic agents and SSI for patients undergoing mostly clean-contaminated surgery from January 2011 through June 2012. Multivariate regression modeling predicted expected rates of SSI. Risk adjusted event rates (RAERs) of SSI were compared across groups using proportionality testing.
Among 7,669 patients, the rate of SSI was 4.6%. The RAERs were 0.85 (p ¼ 0.28) for chlorhexidine (CHG), 1.10 (p ¼ 0.06) for chlorhexidine in isopropyl alcohol (CHGþIPA), 0.98 (p ¼ 0.96) for povidone-iodine (PVI), and 0.93 (p ¼ 0.51) for iodine-povacrylex in isopropyl alcohol (IPCþIPA). The RAERs were 0.91 (p ¼ 0.39) for the non-IPA group and 1.10 (p ¼ 0.07) for the IPA group. Among elective colorectal patients, the RAERs were 0.90 (p ¼ 0.48) for CHG, 1.04 (p ¼ 0.67) for CHGþIPA, 1.04 (p ¼ 0.85) for PVI, and 1.00 (p ¼ 0.99) for IPCþIPA. CONCLUSIONS: For clean-contaminated surgical cases, this large-scale state cohort study did not demonstrate superiority of any commonly used skin antiseptic agent in reducing the risk of SSI, nor did it find any unique effect of isopropyl alcohol. These results do not support the use of more expensive skin preparation agents. (J Am Coll Surg 2014;218:336e344. Ó 2014 by the American College of Surgeons) Surgical site infections (SSIs) are an important source of morbidity and mortality, occurring in approximately 500,000 patients in the United States each year. 1 They increase mortality, hospital length of stay (LOS), and costs of care. 2 Several methods attempt to reduce the incidence and deleterious effects of SSIs. Chlorhexidine in 70% isopropyl alcohol skin antisepsis has been shown to be effective in preventing central venous catheter-associated infections and is currently recommended by the Centers for Disease Control (CDC) as the agent of choice for this indication. 3 No such recommendation exists for surgical procedures overall. Preoperative skin antisepsis varies among and within hospitals. There are 2 major classes of skin antiseptic agents commonly used in the United States: chlorhexidine-based agents and iodophor-based agents. These 2 classes are further divided into agents that include an alcohol agentdtypically CME questions for this article available at http://jacscme.facs.org Disclosure Information: Authors have nothing to disclose. Timothy J Eberlein, Editor-in-Chief, has nothing to disclose. Financial support: SCOAP is a program of the Foundation for Healthcare Quality and is supported by a grant from Washington State's Life Science Discovery Fund and Agency for Healthcare Research and Quality Grant Number 1 R01 HS 20025-01. None of the authors has any financial or personal conflicts of interests pertaining to this work. This work was supported by NIH training grant 1T32DK070555-01A1. isopropyl alcohol (IPA)dand those that do not. The relatively small body of literature examining the impact of preoperative antiseptic agents on risk of SSI has produced mixed results. A systematic review of chlorhexidine-based antisepsis vs iodophor-based antisepsis found chlorhexidine (CHG) to be the superior agent. 4 Maiwald and Chan 5 also found evidence to support the use of chlorhexidine in isopropyl alcohol over aqueous iodophor preparations, but noted that the effect was incorrectly attributed to chlorhexidine exclusively, rather than to the combination of chlorhexidine and alcohol in the majority of papers. Darouiche and colleagues 6 found 2% chlorhexidine-gluconate in 70% IPA (CHGþIPA) reduced the risk of SSI by 41% compared with povidone-iodine (PVI). However, Swenson and colleagues 7 reported no significant difference between iodophor-based antisepsis in combination with alcohol (PVIþIPA or iodine povacrylex in 74% IPA [IPCþIPA]) compared with CHGþIPA.
Despite this inconsistency in the literature, proper antisepsis plays a pivotal role in reducing SSI, and further clarifying the optimal strategy has the potential to affect the incidence of SSIs. There is also a significant cost differential between antiseptic agents, and costs should be considered alongside benefits. The aims of this study were to further evaluate the comparative effectiveness of 4 commonly used surgical skin antiseptic agents in a general surgery population and to determine if IPA has any unique effect on the risk of SSI.
METHODS

Study design
The Comparative Effectiveness Translational Network (CERTAIN) is an Agency for Healthcare Research and Quality-funded research platform directed from the University of Washington's Surgical Outcomes Research Center. The CERTAIN applies skills in comparative evaluation to prospective data collection activities across Washington State. For this research question, CERTAIN assembled a prospective cohort of patients who underwent surgery from January 2011 to June 2012 in Washington State, whose care was monitored through the Surgical Care and Outcomes Assessment Program (SCOAP). We included patients for whom preoperative antiseptic agent data were available. Patients who received more than 1 class of antiseptic agent were excluded. Patients undergoing appendectomies were excluded because the SCOAP data collection is abbreviated for these patients and the typical LOS is less than 24 hours, limiting assessment for SSI. This prospectively gathered clinical registry includes more than 50 Washington State hospitals. For this study, data from 47 SCOAP hospitals were available during the evaluation period. Records from SCOAP were used to obtain demographic, laboratory, anthropometric, procedure, and clinical characteristics, as well as laboratory values, operation type, level or urgency, and perioperative information deemed to be relevant to the risk of SSI.
Data source
The SCOAP is a physician-led surveillance and response system for surgical quality. Its mission is to improve the quality of surgical care by reducing variations in outcomes and processes of care using benchmarking initiatives and data sharing between participants. The SCOAP system monitors the incidence of SSI in participating hospitals by collecting data on factors relevant to SSI. Examples include perioperative patient temperature, appropriate antibiotic prophylaxis, perioperative glucose levels, comorbidities, and type of preoperative antisepsis used. It also includes information on the diagnosis of SSI before discharge. Data are captured for specific procedures performed at participating hospitals. These include bariatric procedures, colectomy, appendectomy, hysterectomy, and for a subset of hospitals, oncologic surgical procedures related to the breast (mastectomy only), lung, esophagus, liver, pancreas, kidney, and prostate. This research project was reviewed and approved by the University of Washington Human Subject Division Institutional Review Board.
Definitions
Data definitions for SCOAP variables are publically available (http://www.scoap.org). Beginning in 2011, SCOAP added an SSI data metric, and abstracters were trained to review the medical record for diagnosed SSIs, as well as information about reintervention including reopening of wound edges, antibiotics for treatment of infection, abscess drainage, drain placement, or reoperation. For the purposes of this study, a patient was considered to have Abbreviations and Acronyms
an SSI if the SCOAP data indicated an SSI, wound edges were reopened with or without antibiotic treatment, an abscess was drained, or reintervention for drainage was performed. For comorbid conditions, a score modeled on the Charlson comorbidity index was calculated on the basis of health conditions identified from the medical record. Because perioperative hypothermia and hyperglycemia have been shown to be associated with risk of SSI, we dichotomized perioperative temperature and blood glucose to reflect normal (temperature ! 35 C, blood glucose 180 mg/dL) or abnormal (temperature < 35 C, blood glucose >180 mg/dL). 8, 9 Statistical analysis The primary outcome in our study was SSI during the index hospitalization. The primary exposure was the type of preoperative skin antiseptic agent used. Patient characteristics were summarized using frequency distributions for categorical variables and using means and standard deviations for continuous variables. To evaluate for differences in categorical and continuous variables, chi-square and multiple t-tests were performed, respectively.
Logistic regression models, accounting for clustering at the hospital level, were developed to evaluate the association between preoperative antiseptic agent and SSI, adjusting for patient, clinical, and operative characteristics. Covariates were selected if they were associated with SSI (p < 0.05) in univariate analyses or if found to be important in previous studies. A priori selected covariates included patient age, procedure type, procedure duration, operative approach, comorbid conditions, American Society of Anesthesiologists (ASA) classification, body mass index, immunocompromised states including diabetes mellitus, active smoking, systemic corticosteroid usage, low serum albumin, and perioperative hyperglycemia. Logistic regression with all covariates except antiseptic agent calculated predicted rates of SSI for each group of patients. This was compared with the observed rate, stratified by antiseptic agent, and riskadjusted event rates (RAERs) were calculated. The patient population was then stratified based on the presence or absence of IPA in the antiseptic agent (CHG and PVI vs CHGþIPA and IPCþIPA), and the analysis was repeated to assess for unique effects of IPA.
Different clean-contaminated cases carry different risks for SSI based on which organ space is being violated and the associated colonizing organisms. This risk is further affected by the priority of the procedure, with urgent or emergency procedures carrying higher risk. Because of significantly different baseline characteristics and observed rates of infection between procedure types and antiseptic agent cohorts, a planned subgroup analysis was performed for patients undergoing elective colorectal surgery. Last, because our data included only information from the index admission, and the recognition of SSIs is time dependent, a sensitivity analysis of patients with an LOS greater than 10 days was performed.
We performed an analysis of propensity to receive different skin antiseptic agents. This sensitivity analysis showed that only procedure type (bariatric vs colorectal), laparoscopic surgical approach, obesity, and diabetes were associated with higher chances of receiving a specific skin antiseptic agent, in this case CHGþIPA. There were not statistically significant differences between hospitals in the use of different agents after controlling for case-mix. Because these factors were risk-adjusted for during logistic regression, we had more than 10 events per covariate, and propensity analysis does not further adjust for potential unmeasured confounding and in fact may accentuate the effect of unmeasured covariates, we did not perform further analysis based on propensity scores for skin antiseptic agent. 10 We used STATA version 12 statistical software (Stata-Corp) for all analyses. Values of p < 0.05 were considered statistically significant.
RESULTS
We identified 7,669 patients (mean [SD] age, 57.5 [16.2] years, 39% male, 60% colorectal, 34% bariatric, 6% other) who underwent surgery at SCOAP site hospitals. The overall rate of SSI was 4.6% (6.6% colorectal, 1.4% bariatric, 1.5% other, p < 0.01). All cases were classified as clean-contaminated. There were significant baseline differences in clinical and demographic characteristics among the cohorts (Table 1 ). Observed differences in body mass index were related to differences in antiseptic agent use in bariatric vs colorectal cases.
The unadjusted rates of SSI were 4.0% for CHG, 4.5% for CHGþIPA, 6.0% for PVI, and 5.3% for IPCþIPA (p ¼ 0.25). Comparison of these observed rates with predictions yielded RAERs of 0.85 (p ¼ 0.28) for CHG, 1.10 (p ¼ 0.06) for CHGþIPA, 0.98 (p ¼ 0.96) for PVI, and 0.93 (p ¼ 0.51) for IPCþIPA. Table 2 shows the antiseptic agent-specific observed rates of infection, predicted rates of infection, and RAERs with 95% confidence intervals.
Patients were then stratified based on the inclusion of IPA in the antiseptic agent used and the analysis repeated. The unadjusted rate of SSI in the non-IPA group was 4.5% compared with 4.6% in the IPA group (p ¼ 0.87). Comparison of these observed rates to predictions yielded RAERs of 0.91 (p ¼ 0.39) for the non-IPA group and 1.10 (p ¼ 0.07) for the IPA group. Table 4 shows the agent-specific observed rates of infection, predicted rates of infection, and RAERs with 95% confidence intervals for elective colorectal cases. Given our sample sizes and event rates among elective colorectal There were no significant differences between groups ( Table 5 ). There were no significant differences in the proportion of each group that had LOS greater than 10 (Table 6 ). Our statistical power to detect even a 25% risk reduction of CHGþIPA compared with PVI in this group was >0.99. 
DISCUSSION
We report the results of a large prospective statewide cohort study evaluating the association of commonly used skin antiseptic agents and the risk of SSI. We found wide variation in the use of antiseptic agents across sites and type of general surgical procedures. As Table 1 shows, there was significant variability in the populations for each antiseptic agent group. On further analysis, the bulk of this variability was explained by the distribution of bariatric cases being heavily skewed toward the CHG and CHGþIPA groups. Despite this variability, the large size of our cohort allowed us to risk-adjust for these differences without compromising statistical veracity, and after adjusting for relevant factors, we found that no single antiseptic agent was associated with a comparatively lower risk of SSI. Most studies assessing the efficacy of different antiseptic agents in surgical procedures have relied on surrogate end points (eg, bacterial colonization). In part, this is because many studies have focused on clean surgical procedures (foot and ankle, spine), in which the infection rate is very low and the only sources of pathogens are skin flora or breaks in sterile technique. In the general surgical population, the intraluminal bowel flora may be a source of pathogenic bacteria. Tschudin-Sutter and colleagues 11 found no correlation between preoperative skin flora and pathogens isolated from SSI wounds in more than 1,000 general surgery patients, suggesting that bowel flora may be a potential source. There has been no evidence that skin antiseptic agents are effective in preventing the transfer of pathogenic organisms from intraluminal sites to the wound site.
Despite this, several studies have indicated a benefit to certain agents in a mix of clean and clean-contaminated procedures. A systematic review by Lee and associates 4 comparing CHG-based antisepsis with iodophor-based antisepsis found CHG to be superior, but the cases included were predominantly clean, with fewer cleancontaminated cases. Only a single studydone by Darouiche and coworkers 6 dwas powered to detect a difference in SSI between groups in clean-contaminated procedures. There was wide variation in the agents compared; most studies compared single with dual agents. Only 2 of the 9 studies include IPA in both comparator groups, limiting our ability to distinguish a unique treatment effect of the nonalcohol agent. Maiwald and Chan 5 found that many studies comparing chlorhexidine in isopropyl alcohol (CHGþIPA) antiseptic agents to iodophor-based agents attributed observed differences to the CHG moiety without evaluating the effect of the alcohol component. This study specifically addressed this issue and found neither a unique benefit of CHG nor of alcohol, together or in combination with other agents.
Recently, 2 large-scale studies addressed the issue of antiseptic agents in the general surgery population using more rigorous methodologies. Swenson and colleagues 7 compared 3 protocols using a time-sequence approach: CHGþIPA alone; a sequence of 10% PVI, then separate application of 70% IPA followed by another application of PVI; and iodine-povacrylex in 74% isopropyl alcohol (IPCþIPA). They reported significantly lower rates of SSI in patients prepared with PVIþIPA or IPCþIPA compared with patients prepared with CHGþIPA (4.8% vs 4.8% vs 8.2%, p ¼ 0.001). This difference was attributable to different rates of superficial SSI because there were no observed differences in rates of deep and/or organ-space SSI. When Swenson and colleagues 7 performed a pooled analysis of CHGþIPA compared with any iodophorbased preparation with alcohol, they found a nonsignificant trend toward higher odds of infection in the CHGþIPA group (odds ratio 1.35 [95% CI 0.97 to 1.87], p ¼ 0.07). Contrary to Swenson's study, in a randomized controlled trial (RCT) by Darouiche and colleagues, 6 the use of CHGþIPA was associated with a 41% lower risk of SSI (relative risk 0.59 [95% CI 0.41 to 0.85], p < 0.01) compared with PVI alone. They observed a difference in both superficial and deep SSIs favoring CHG-IPA, with no observed difference in organ-space SSI. That study could not distinguish individual treatment effect of chlorhexidine or alcohol because the 2 agents were used together only in a single arm of the trial. Although the study by Darouiche and colleagues 6 was a multicenter RCT with strong methodologic quality, it represents a single trial with results that have not been reproduced to date. If the effect size for CHGþIPA in reducing SSI described by Darouiche and colleagues 6 is valid, we would expect to see similar trends in ours and other large-scale studies. The results published by Swenson and colleagues 7 differ significantly from those observed by Darouiche and coworkers. 6 Furthermore, the results of RCTs are not always reproduced in other settings, highlighting the potentially significant difference between efficacy in the tightly controlled conditions of an RCT vs effectiveness in the less controlled conditions of regular clinical practice. Two recent pharmaceutical studies demonstrated reproducibility rates of published data ranging from 11% to 25%. 12, 13 Reasons why the results from the much larger-scale Swenson and coauthors 7 study and our current SCOAP analysis may not support the findings of the RCT by Darouiche include differential application of agents outside the context of an RCT (efficacy vs effectiveness), unmeasured confounding in the ways patients are selected for use of different agents, and varied approaches to measuring infection. Similar rates of infection are seen in the CHGþIPA group across the Swenson 7 and Darouiche 6 studies, which focused on 30-day surveillance (10.7% vs 9.5%). The SCOAP currently captures data only from index admissions, so as expected, the rates of infection are lower, but appear similar to the 10-day data reported by Darouiche and associates. 6 A differential effect of antiseptic agents after discharge from hospital has not been suggested.
There are limitations to this study. The SCOAP database currently contains information from the index hospitalization. It does not identify SSIs diagnosed after discharge and therefore underestimates the true rate of SSI. This is important because recent data suggest that 50% or more of SSIs are diagnosed postdischarge. 14 The commonly accepted timeframe within which most SSIs occur is 3 to 10 days postoperatively and the average length of stay among our patients was 6 to 7 days. So, procedures with shorter average LOS (bariatric, laparoscopic) might have a higher percentage of "missed" SSI diagnoses. As Table 1 shows, the patients in the CHG and CHGþIPA groups had significantly younger age, shorter average LOS, higher proportions of laparoscopic procedures, fewer colorectal procedures, fewer urgent/ emergency procedures, fewer smokers, and fewer patients with low serum albumin. These subpopulation differences, both in characteristics and LOS, represent a selection bias, but one that would be expected to bias toward CHG and CHG-IPA as a more effective agent. Our analysis of patients with LOS greater than 10 days showed results similar to those of the larger cohorts. Although the crude rates of SSI are high because restriction to patients with longer than average LOS will preferentially select patients who have had complicating factors, there were no differences in the rates with which patients receiving different antiseptic agents had prolonged LOS.
CONCLUSIONS
In conclusion, this large-scale regional cohort study did not demonstrate superiority of any commonly used skin antiseptic agent in reducing the risk of SSI. Furthermore, our data do not support any risk reduction associated with the use of isopropyl alcohol in antiseptic agents. Determining the impact of different antiseptic agents is relevant to all hospitals and ambulatory surgery centers as they try to use their limited resources to reduce the rates of costly SSIs. Although the cost of antiseptic agents is quite low, transitioning from the use of more expensive agents to equally effective but less expensive agents could result in considerable savings across the millions of procedures performed each year. This study demonstrates the value of evaluating the "real-world" effectiveness of an intervention aimed at improving outcomes. These results do not support the use of more expensive antiseptic agents, and because no single agent was found to be superior, standardizing skin antiseptic choice may not be a high value target for quality improvement.
